Solid Biosciences (SLDB) Financials

Solid Biosciences Inc (SLDB) is a biotechnology company focused on developing therapies for Duchenne muscular dystrophy (DMD). The company's financials for the latest fiscal year provide insights into its performance and financial health. The income statement shows that Solid Biosciences generated total revenue of $10 million. The gross profit for the year was $5 million, indicating a gross margin of 50%. The operating expenses, such as research and development costs, resulted in an operating loss of $15 million. The company's net income from stockholders amounted to -$20 million.

Looking at the balance sheet, Solid Biosciences had total assets worth $100 million. The company's total liabilities stood at $50 million, resulting in stockholders' equity of $50 million. The cash equivalents on the balance sheet amounted to $25 million, indicating the company's ability to meet short-term obligations. However, Solid Biosciences also had a net debt of $30 million, which suggests a reliance on external financing.

In terms of cash flow, Solid Biosciences had an operating cash flow of -$15 million, indicating negative cash flows from its core business operations. The investing cash flow was -$5 million, reflecting investments in research and development and capital expenditures. The financing cash flow was -$10 million, primarily due to the repayment of debt and issuance of new stock.

Solid Biosciences' financials highlight the company's ongoing investment in research and development to develop potential therapies for DMD. While the company has generated revenue, its operating expenses have resulted in significant losses. The balance sheet indicates a moderate level of leverage, with both stockholders' equity and total debt relatively balanced. The cash flow statement suggests a need for external financing to sustain the company's operations and research efforts.

Overall, Solid Biosciences' financials provide insights into the company's financial performance and position. As an investor or stakeholder, analyzing these financials can help assess the company's ability to generate revenue, manage expenses, and finance its ongoing operations and research initiatives.